Researchers at Alexion, AstraZeneca Rare Disease are conducting a clinical study for adults with generalized myasthenia gravis (gMG) who are currently receiving ravulizumab treatment. The study will evaluate whether a planned schedule for gradually lowering oral corticosteroids (OCS) can safely help patients reduce or stop these medications while keeping their gMG symptoms stable.
The study
This is a prospective, multicenter, single-arm study involving adults with acetylcholine receptor–positive (AChR+) gMG who receive intravenous ravulizumab every eight weeks. Researchers will follow participants using a predefined schedule to slowly reduce their corticosteroid dose and monitor the safety and effectiveness of this approach.
Participation in the study will last approximately six months and will include about three to five clinic visits during that time. At these visits, participants will complete patient-reported outcome (PRO) questionnaires about their symptoms and experiences, and provide a small number of blood (serum) samples for study assessments.
Study criteria
To be eligible, individuals must meet the following inclusion criteria:
- Be 18 years of age or older
- Have a diagnosis of generalized myasthenia gravis (gMG)
- Be currently receiving ravulizumab treatment
- Be taking oral corticosteroids equivalent to at least 7.5 mg of prednisone/prednisolone daily for at least four weeks before enrollment
Additional eligibility criteria may apply. Please visit this link for the full listing of inclusion and exclusion criteria.
Interested in participating?
Travel support is available for eligible participants and their families.
To learn more about the study or inquire about participation, please contact the study coordinator by email: alexion_octagon@iqvia.com.
The Muscular Dystrophy Association does not endorse specific products or brands.
The post Clinical Research Alert: Clinical Study for Adults with Generalized Myasthenia Gravis (gMG) appeared first on Quest | Muscular Dystrophy Association.